Floatz Rating
B62/100
Confidence
Indicative
Sponsor
GBG Forschungs GmbH
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06201234CT.gov Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT06120283CT.gov BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05573126CT.gov Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Tumor Luminal A Or B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elacestrant (this asset) | GBG Forschungs GmbH | P2 | B · 62 |
| Letrozole | BeOne Medicines | P4 | BB |
| Fulvestrant | BeiGene | P2/3 | B |
| Cyclophosphamide | Puma Biotechnology, Inc. | P3 | B |
| Carboplatin | Fudan University | P3 | B |
| Epirubicin | Fudan University | P3 | B |
| Palbociclib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P2/3 | B |
| Durvalumab | University Health Network, Toronto | P2 | B |
| Docetaxel | Fudan University | P3 | B |
+16 more in the Breast Tumor Luminal A Or B cohort
Other indications for Elacestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P3 | BB · 70 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 68 |
| Breast Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Elacestrant in Breast Tumor Luminal A Or B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elacestrant-breast-tumor-luminal-a-or-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →